Alkem Laboratories Share Price

â‚ą 5,113.50

+â‚ą34.50 (0.68%)
1D
Last updated 30 Oct, 2026, 15:50 IST
NSE: ALKEM
|
Pharmaceuticals

Alkem Laboratories Share Price Today

As of 1 Nov 2026, Alkem Laboratories share price is â‚ą5,113.50. The stock opened at â‚ą5,060.50, compared to its previous close of â‚ą5,079.00. During today's trading session, Alkem Laboratories share price moved in the range of â‚ą5,030.00 to â‚ą5,134.50, with an average price of â‚ą5,082.25 for the day. Looking at its last 52-week, the stock has touched a low of â‚ą4,811.00 and a high of â‚ą5,933.50. On the performance front, Alkem Laboratories share price has declined by 5.31% over the last six months and is down 7.45% on a year-on-year basis.

Share price over the last 1 day rose from 5078.00 to 5113.50, ranging between 5030.00 and 5128.50.
â‚ą5,030.00
0.68% up today
â‚ą5,134.50
1D LOW
1D HIGH

Alkem Laboratories Stock Insights

Latest Earning
Op Profit TrendUp by 82.57% QoQ
Latest Earning
Net Profit TrendUp by 107.20% QoQ
Latest Earning
Revenue TrendUp by 2.35% QoQ
Stock Performance
OutperformingBeat Nifty by 1.37 % in last 1 year
Shareholding Pattern
DIIDII decreased stake by 15.03%
Shareholding Pattern
FIIFII decreased stake by 0.89%
Technical Indicators
MACD CrossThe MACD line crossed above the signal line on 1 Day interval.
Alkem Laboratories stock performance
Openâ‚ą5,060.50
Highâ‚ą5,134.50
Lowâ‚ą5,030.00
Prev. closeâ‚ą5,079.00
Alkem Laboratories trading activity
Volume1,08,036
Average traded priceâ‚ą5,085.08
Last traded time03:50:00 30 Oct
Last traded quantity10
Circuit
L
H
â‚ą4,602.50
â‚ą5,624.50
52-week
L
H
â‚ą4,811.00
â‚ą5,933.50
Mkt Cap Cr
61,277.06
P/E
27.8
P/B
4.43
ROA
10.57%
ROE
16.66%
ROCE
18.61%
Quick Ratio
1.86
EV/EBITDA
17.84

Based on fundamentals, this stock's

Performance: 3 out of 5, Neutral
Performance
Neutral
Alkem Lab performance is moderate compared to markets
Valuation: 1 out of 5, Overvalued
Valuation
Overvalued
Alkem Lab appears overvalued compared to its peers
Earnings: 5 out of 5, Excellent
Earnings
Excellent
Alkem Lab revenue, operating profit and net profit are growing
Peer Comparison
Peer comparison — key ratios
NameMkt Cap CrP/EP/BROAROEROCEQuick RatioEV/EBITDA
Sun Pharmaceutical Industries4,26,661.7438.834.789.61%13.79%18.65%2.3122.27
Divis Laboratories2,57,902.7388.1715.3914.6%15.32%19.56%3.558.97
Torrent Pharmaceuticals1,76,306.2184.09.64.7%11.42%11.37%0.7533.6
Laurus Labs1,29,242.6897.021.3311.58%22.11%20.91%0.6854.77
Zydus Lifesciences1,24,089.4827.024.588.57%18.59%17.35%0.9116.42
Dr. Reddy's Laboratories1,12,698.5340.842.94.79%7.21%8.58%1.3519.05
Cipla1,11,486.1439.063.156.6%8.18%10.8%2.521.03
Mankind Pharma1,02,796.6045.425.857.82%12.76%14.68%0.7425.01
Aurobindo Pharma96,536.9026.022.556.34%9.25%11.76%1.1512.38
Lupin91,870.1616.554.0914.47%23.76%24.88%1.429.83

Auto-generated based on historical fundamentals; not a recommendation to buy/sell.

Alkem Laboratories Company Background

ISIN
INE540L01014
Sector Market Cap
â‚ą 61,277.06 Cr

Alkem Laboratories Ltd. is an India-based pharmaceutical company engaged in the development, manufacturing, and sale of pharmaceutical products. The Company operates in a single business segment-Pharmaceuticals. It produces branded generics, generic drugs, active pharmaceutical ingredients (APIs), and nutraceuticals, which it markets in India and international markets. It has a portfolio of approximately 800 brands in India and maintains a presence in over 40 international markets, with the United States being its key focus market. Its offerings include therapies, prescription (Rx) products, and Alkem generics. Its therapy offerings cover multiple medical fields, including anti-infectives, anti-osteoporosis, cardiology, neurology, dermatology, diabetology, gastroenterology, gynecology, oncology, ophthalmology, respiratory care, rheumatology, and urology. The Company’s subsidiaries include Ascend Laboratories (Pty) Ltd, Pharmacor Pty Limited, Alkem Laboratories Corporation, and others.

Alkem Laboratories Financial Highlights

  • Revenue: Alkem Laboratories reported revenue of â‚ą15,295.62 crore in FY26 vs â‚ą13,458.26 crore in FY25. It showed an increase of 13.65% on a yearly basis.
  • Operating Profit: Alkem Laboratories reported an operating profit of â‚ą2,870.89 crore in FY26 vs â‚ą2,527.03 crore in FY25. It showed an increase of 13.61% on a year-on-year basis.
  • Net Profit: Alkem Laboratories reported a net profit of â‚ą2,353.13 crore in FY26 vs â‚ą2,216.00 crore in FY25. It showed an increase of 6.19% on a yearly basis.

Alkem Laboratories Quarterly Result Highlights

  • Alkem Laboratories reported revenue of â‚ą3,892.90 crore in Jun 2026, compared with â‚ą3,803.39 crore in Mar 2026, representing an increase of 2.35% on a quarter-on-quarter (QoQ) basis.
  • Alkem Laboratories reported an operating profit of â‚ą771.99 crore in Jun 2026, compared with â‚ą422.85 crore in Mar 2026, representing an increase of 82.57% on a quarter-on-quarter (QoQ) basis.
  • Alkem Laboratories reported a profit of â‚ą521.49 crore in Jun 2026, compared with â‚ą251.68 crore in Mar 2026, reflecting an increase of 107.20% on a QoQ basis.
  • The earnings per share (EPS) of Alkem Laboratories stood at â‚ą192.51 during Jun 2026.

Data Source: BSE, Company announcements

Securities shown are illustrative, not recommendations. Past performance does not guarantee future results.

Promoters
49.70%
FII
10.32%
Other DII
5.04%
Retail and other
17.15%
Mutual funds
17.79%
Foreign Institutional Investor (FII)
FII shareholding by period
Dec 20259.97%
Mar 202610.16%
Jun 202610.42%
Sep 202610.32%

Alkem Laboratories Investment Returns

1 day
+0.68%
1 week
+3.37%
1 month
-0.97%
1 year
-7.45%
3 years
+38.51%
5 years
+41.62%

Alkem Laboratories Share Price History

Alkem Laboratories share price history by day, showing open and close prices and the percentage change
Day
Open / Close
Change %
30 Oct 26
â‚ą5,060.50 / â‚ą5,113.50
+0.68%
29 Oct 26
â‚ą5,093.00 / â‚ą5,079.00
+0.18%
28 Oct 26
â‚ą5,076.00 / â‚ą5,070.00
-0.16%
27 Oct 26
â‚ą4,990.00 / â‚ą5,078.00
+0.95%
Show more

Alkem Laboratories Financials

Full statement

Income Statement · Consolidated

Income Statement · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Revenueâ‚ą14,712.27â‚ą12,964.52â‚ą12,667.58â‚ą11,599.26
Other Incomeâ‚ą583.35â‚ą493.74â‚ą310.84â‚ą216.08
Total Revenueâ‚ą15,295.62â‚ą13,458.26â‚ą12,978.42â‚ą11,815.34
Total Expensesâ‚ą12,249.90â‚ą10,931.23â‚ą10,833.80â‚ą10,407.59
Profit Before Taxâ‚ą2,870.89â‚ą2,527.03â‚ą2,023.13â‚ą1,304.77
Taxâ‚ą517.76â‚ą311.03â‚ą211.67â‚ą297.96
Profit After Taxâ‚ą2,353.13â‚ą2,216.00â‚ą1,811.46â‚ą1,006.81
EPS - Basicâ‚ą192.51â‚ą181.11â‚ą150.19â‚ą82.31
EPS - Dilutedâ‚ą192.51â‚ą181.11â‚ą150.19â‚ą82.31

Cash Flow · Consolidated

Cash Flow · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Profit before taxâ‚ą2,870.89â‚ą2,527.03â‚ą2,023.13â‚ą1,304.77
Income before WC changesâ‚ą3,007.22â‚ą2,630.83â‚ą2,406.70â‚ą1,629.12
Change in Assets-â‚ą663.72-â‚ą454.79-â‚ą430.50â‚ą261.69
Change in Liabilitiesâ‚ą248.55â‚ą240.82â‚ą378.81â‚ą65.08
Change in WC-â‚ą415.17-â‚ą213.97-â‚ą51.69â‚ą326.77
Cash flow from Operationsâ‚ą1,963.03â‚ą1,912.84â‚ą1,948.07â‚ą1,682.50
Cash flow from Investing-â‚ą1,667.21-â‚ą1,298.76-â‚ą1,008.50â‚ą112.84
Cash flow from Financing-â‚ą503.40-â‚ą810.99-â‚ą1,145.01-â‚ą1,760.82
Total Cash Flow-â‚ą207.58-â‚ą196.91-â‚ą205.44â‚ą34.52
Cash (Start of the year)-â‚ą120.09â‚ą66.31â‚ą273.80â‚ą232.18
Cash (End of the year)-â‚ą342.13-â‚ą120.09â‚ą66.31â‚ą273.80

Balance Sheet · Consolidated

Balance Sheet · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Non-Current Assetsâ‚ą8,662.45â‚ą6,879.91â‚ą5,163.32â‚ą5,026.95
Current Assetsâ‚ą12,210.52â‚ą10,811.19â‚ą10,411.58â‚ą8,729.70
Total Assetsâ‚ą20,872.97â‚ą17,691.10â‚ą15,574.90â‚ą13,756.65
Current Liabilitiesâ‚ą4,782.70â‚ą3,960.67â‚ą3,994.55â‚ą3,707.15
Net Current Assetâ‚ą7,427.82â‚ą6,850.52â‚ą6,417.03â‚ą5,022.55
Non-Current Liabilitiesâ‚ą1,741.34â‚ą1,296.80â‚ą865.95â‚ą614.50
Equity Capitalâ‚ą14,348.93â‚ą12,433.63â‚ą10,714.40â‚ą9,435.00
Total Equity & Liabilitiesâ‚ą20,872.97â‚ą17,691.10â‚ą15,574.90â‚ą13,756.65

Income Statement · Standalone

Income Statement · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Revenueâ‚ą9,663.91â‚ą8,813.44â‚ą7,963.85â‚ą9,054.55
Other Incomeâ‚ą555.17â‚ą507.06â‚ą305.99â‚ą266.29
Total Revenueâ‚ą10,219.08â‚ą9,320.50â‚ą8,269.84â‚ą9,320.84
Total Expensesâ‚ą7,553.37â‚ą7,016.96â‚ą6,611.88â‚ą7,993.85
Profit Before Taxâ‚ą2,522.62â‚ą2,303.54â‚ą1,594.13â‚ą1,326.99
Taxâ‚ą337.50â‚ą213.82â‚ą33.62â‚ą192.52
Profit After Taxâ‚ą2,185.12â‚ą2,089.72â‚ą1,560.51â‚ą1,134.47
EPS - Basicâ‚ą190.87â‚ą190.77â‚ą146.13â‚ą94.88
EPS - Dilutedâ‚ą190.87â‚ą190.77â‚ą146.13â‚ą94.88

Cash Flow · Standalone

Cash Flow · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Profit before taxâ‚ą2,671.67â‚ą2,597.39â‚ą1,881.03â‚ą1,326.99
Income before WC changesâ‚ą2,606.70â‚ą2,546.05â‚ą2,092.77â‚ą1,455.88
Change in Assets-â‚ą250.29-â‚ą179.20-â‚ą238.27â‚ą169.14
Change in Liabilitiesâ‚ą94.19â‚ą219.19â‚ą184.89â‚ą36.56
Change in WC-â‚ą156.10â‚ą39.99-â‚ą53.38â‚ą205.70
Cash flow from Operationsâ‚ą1,969.12â‚ą2,189.41â‚ą1,686.56â‚ą1,437.42
Cash flow from Investing-â‚ą1,461.25-â‚ą1,007.41-â‚ą865.60â‚ą197.04
Cash flow from Financing-â‚ą672.82-â‚ą1,036.89-â‚ą959.04-â‚ą1,711.27
Total Cash Flow-â‚ą164.95â‚ą145.11-â‚ą138.08-â‚ą76.81
Cash (Start of the year)â‚ą12.04-â‚ą133.07â‚ą5.01â‚ą81.82
Cash (End of the year)-â‚ą152.91â‚ą12.04-â‚ą133.07â‚ą5.01

Balance Sheet · Standalone

Balance Sheet · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Non-Current Assetsâ‚ą9,431.01â‚ą8,241.60â‚ą5,997.72â‚ą5,959.01
Current Assetsâ‚ą7,830.12â‚ą7,354.00â‚ą8,040.08â‚ą6,772.21
Total Assetsâ‚ą17,261.13â‚ą15,595.60â‚ą14,037.80â‚ą12,731.22
Current Liabilitiesâ‚ą2,746.81â‚ą2,543.44â‚ą3,106.40â‚ą3,044.83
Net Current Assetâ‚ą5,083.31â‚ą4,810.56â‚ą4,933.68â‚ą3,727.38
Non-Current Liabilitiesâ‚ą515.56â‚ą730.33â‚ą376.79â‚ą336.54
Equity Capitalâ‚ą13,998.76â‚ą12,321.83â‚ą10,554.61â‚ą9,349.85
Total Equity & Liabilitiesâ‚ą17,261.13â‚ą15,595.60â‚ą14,037.80â‚ą12,731.22
* All values are in INR Crore
Alkem Laboratories market depth
Bid quantityBid priceAsk priceAsk quantity
415113.500
0000
0000
0000
0000
Total bid quantity41
Total ask quantity0
Alkem Laboratories technical summary
Bearish indicators4
Neutral indicators4
Bullish indicators0
OverallStrong Bearish
by SEBI experts

Expert Pick

EXPPICK
Stop-loss
Stop-loss is locked. Sign in to view.
Entry price
Entry price is locked. Sign in to view.
Target
Target is locked. Sign in to view.
Indicator
Value
Verdict
RSI (14)
47.24
Neutral
ATR (14)
126.57
Neutral
STOCH(9,6)
85.21
Bearish
STOCH RSI (14)
92.51
Bearish
ADX(9)
24.92
Bearish
UO(9)
67.43
Neutral
ROC(12)
-2.6
Bearish
WillR(14)
-38.2
Neutral
Period
Simple value
Exponential vaue
5D
5074.1
5077.68
10D
5040
5080.51
20D
5138
5121.35
50D
5222.04
5223.93
100D
5378.36
5309
Volume trend — traded volume by day
30 Oct1L
29 Oct0L
28 Oct0L
27 Oct1L
26 Oct0L
Average0L

Technical indicators used here are for indicative purposes only. Kindly do not treat it as an investment or trading advice

Compare against other stocks

Alkem Laboratories
Pharmaceuticals
Add Stock
Add Another

Mutual Funds Invested in Alkem Laboratories

Fund name
AUM
HDFC Pharma and Healthcare Fund
6.21%
Tata Nifty MidSmall Healthcare Index Fund
6.16%
Motilal Oswal Nifty MidSmall Healthcare Index Fund
6.06%

Alkem Laboratories Returns Calculator

Ex-date: 07 Aug 2026
Ex-date: 20 Feb 2026

Alkem Laboratories Latest News

2 weeks ago
Apollo Hospitals, Max Health, Fortis: Healthcare stocks to post strong Q2 earnings; volumes, capacity additions in focus
2 months ago
Alkem Laboratories Q1 results: Net profit drops 21% YoY; board approves setting up new block at Baddi plant
2 months ago
Q1 Results: Ashok Leyland, NMDC, Alkem Labs, Bharat Dynamics, Voltas, Physicswallah, others to post earnings on August 14
4 months ago
Cipla, Alkem, Zydus shares gain as US FDA reportedly approaches Indian firms for cancer drug supply
5 months ago
Stocks to watch, June 3: NHPC, IT stocks, Alkem Labs, IndiGo, Canara Bank, Mankind Pharma
5 months ago
Stocks to watch, June 2: Anant Raj, NHPC, Ola Electric, fertiliser stocks, Wipro, NMDC, Coal India
5 months ago
Q4 results: Ashok Leyland, Bharat Dynamics, Alkem Labs, ITI, Tenneco Clean Air, Prime Focus, others to post earnings on May 28
5 months ago
Wockhardt, Ajanta Pharma, among others fuel Nifty Pharma up over 2%; what’s driving today’s gains?
Showing news item 1 of 8

Top Gainers

LAURUSLABS Share Price
â‚ą2405.50
+161.5 (+7.2%)
TRENT Share Price
â‚ą3017.30
+155.6 (+5.44%)
ZYDUSLIFE Share Price
â‚ą1245.50
+61.1 (+5.16%)
NAVINFLUOR Share Price
â‚ą8680.00
+419.5 (+5.08%)
POONAWALLA Share Price
â‚ą461.70
+20.2 (+4.58%)
See more

Top Losers

INTELLECT Share Price
â‚ą504.55
-98.3 (-16.31%)
REDINGTON Share Price
â‚ą326.95
-30.2 (-8.46%)
SUZLON Share Price
â‚ą33.90
-2.89 (-7.86%)
COHANCE Share Price
â‚ą444.30
-37.05 (-7.7%)
PNCINFRA Share Price
â‚ą123.93
-10.05 (-7.5%)
See more

Alkem Laboratories Share Price FAQs

Please be aware that Alkem Laboratories stock prices are subject to continuous fluctuations due to various factors.